Bronchiolitis: Monoclonal antibody halves hospitalizations of children younger than 6 months old

Bronchiolitis: Monoclonal antibody halves hospitalizations of children younger than 6 months old

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.

Study shows monoclonal antibody can lower common lung infection...

Last Updated on June 5, 2025 by Team THIP New Delhi, June 5 (IANS) A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections in infants can halve hospitalisations for bronchiolitis, according to a study. Bronchiolitis is an acute viral infection that affects the respiratory system of children under one […] The post Study shows monoclonal antibody can lower common lung infection risk appeared…

Monoclonal Antibody Reduces Hospitalizations for Bronchiolitis by 50% in

In a groundbreaking real-world study, researchers have demonstrated that a single dose of nirsevimab, a long-acting monoclonal antibody developed to prevent respiratory syncytial virus (RSV) infections, significantly reduces hospitalizations due to bronchiolitis in infants. This antibody, already approved at the European level for protecting infants during their first exposure season to RSV, has been shown to halve hospital admissions among infa…